Stephen R Rapp, Emily V Dressler, W Mark Brown, James L Wade, Nguyet Le-Lindqwister, David King, Kendrith M Rowland, Kathryn E Weaver, Heidi D Klepin, Edward G Shaw, Glenn J Lesser
PURPOSE: To test efficacy of donepezil, a cognitive enhancer, to improve memory in breast cancer survivors who report cancer-related cognitive impairment 1-5 years postchemotherapy. PATIENTS AND METHODS: Adult female BCS exposed to ≥4 cycles of adjuvant chemotherapy 1-5 years before enrollment who reported cancer-related cognitive impairment were eligible. Participants, enrolled at sites affiliated with the Wake Forest NCI Community Oncology Research Program (NCORP) Research Base, were randomly assigned to receive 5 mg of donepezil once daily for 6 weeks titrated to 10 mg once daily for 18 weeks or placebo...
May 6, 2024: Journal of Clinical Oncology